Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.
“The diseases for which Atsena is developing therapies currently have no approved treatments,” Kenji Fujita, MD, chief medical officer of Atsena, told Healio. “By replacing the defective gene with a healthy copy, Atsena’s approach addresses the root of the pathology.”
The therapy is designed to yield therapeutic levels of gene